Quantitative Magnetic Resonance Techniques as Surrogate Markers of Alzheimer's Disease

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.

Original languageEnglish (US)
Pages (from-to)196-205
Number of pages10
JournalNeuroRx
Volume1
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Alzheimer Disease
Magnetic Resonance Spectroscopy
Biomarkers
Longitudinal Studies
Disease Progression
Amyloid
Positron-Emission Tomography
Molecular Biology
Early Diagnosis
Cross-Sectional Studies
Magnetic Resonance Imaging
Therapeutics
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • magnetic resonance imaging
  • magnetic resonance spectroscopy
  • mild cognitive impairment
  • surrogate marker
  • volumetry

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Quantitative Magnetic Resonance Techniques as Surrogate Markers of Alzheimer's Disease. / Kantarci, Kejal M; Jack, Clifford R Jr.

In: NeuroRx, Vol. 1, No. 2, 04.2004, p. 196-205.

Research output: Contribution to journalArticle

@article{7866956f2dfa40ef84f956ad77fc9d41,
title = "Quantitative Magnetic Resonance Techniques as Surrogate Markers of Alzheimer's Disease",
abstract = "Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.",
keywords = "Alzheimer's disease, magnetic resonance imaging, magnetic resonance spectroscopy, mild cognitive impairment, surrogate marker, volumetry",
author = "Kantarci, {Kejal M} and Jack, {Clifford R Jr.}",
year = "2004",
month = "4",
doi = "10.1602/neurorx.1.2.196",
language = "English (US)",
volume = "1",
pages = "196--205",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Quantitative Magnetic Resonance Techniques as Surrogate Markers of Alzheimer's Disease

AU - Kantarci, Kejal M

AU - Jack, Clifford R Jr.

PY - 2004/4

Y1 - 2004/4

N2 - Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.

AB - Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.

KW - Alzheimer's disease

KW - magnetic resonance imaging

KW - magnetic resonance spectroscopy

KW - mild cognitive impairment

KW - surrogate marker

KW - volumetry

UR - http://www.scopus.com/inward/record.url?scp=23044467324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044467324&partnerID=8YFLogxK

U2 - 10.1602/neurorx.1.2.196

DO - 10.1602/neurorx.1.2.196

M3 - Article

C2 - 15717020

AN - SCOPUS:23044467324

VL - 1

SP - 196

EP - 205

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

IS - 2

ER -